Posted by Michael Wonder on 01 Apr 2025
Nemolizumab for the treatment of patients with moderate to severe atopic dermatitis
27 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of nemolizumab in the NHS in England.
For the time being, nemolizumab when used in combination with a topical corticosteroid, a calcineurin inhibitor, or both, is not recommended for the treatment of patients 12 years of age and older with a body weight of 30 kg or more with moderate to severe atopic dermatitis that is suitable for systemic treatment.
